Your browser doesn't support javascript.
loading
S-Ketamine Mediates Its Acute and Sustained Antidepressant-Like Activity through a 5-HT1B Receptor Dependent Mechanism in a Genetic Rat Model of Depression.
du Jardin, Kristian G; Liebenberg, Nico; Cajina, Manuel; Müller, Heidi K; Elfving, Betina; Sanchez, Connie; Wegener, Gregers.
Afiliação
  • du Jardin KG; Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Liebenberg N; Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Cajina M; Lundbeck US LLC, Paramus, NJ, United States.
  • Müller HK; Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Elfving B; Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Sanchez C; Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Wegener G; Lundbeck US LLC, Paramus, NJ, United States.
Front Pharmacol ; 8: 978, 2017.
Article em En | MEDLINE | ID: mdl-29379439
ABSTRACT
Rationale The mechanisms responsible for the unique antidepressant properties of ketamine have only been partly resolved. Recent preclinical reports implicate the neurotransmitter serotonin [5-hydroxytryptamine (5-HT)] in the antidepressant-like response of ketamine, and modulation of 5-HT1B receptors has been hypothesized to attain an important role.

Objectives:

To evaluate the role of endogenous stimulation of 5-HT1B heteroreceptors in the antidepressant-like activity of S-ketamine.

Method:

Flinders sensitive line (FSL) rats, a genetic model of depression, were depleted of endogenous 5-HT by 4-chloro-DL-phenylalanine methyl ester HCl administration (pCPA; 86 mg/kg/day for 3 days). In pCPA-pretreated and control FSL rats, the acute and sustained effects of a single dose of S-ketamine (15 mg/kg) and the selective 5-HT1B receptor agonist CP94253 (1-6 mg/kg) alone and in combination with S-ketamine were studied in the forced swim test (FST), a commonly used assay that detects antidepressant activity.

Results:

pCPA pretreatment decreased cortical 5-HT levels to ∼6% but did not affect the baseline behavioral phenotype of FSL rats. S-ketamine demonstrated acute and sustained antidepressant-like activity, both of which were abolished by 5-HT depletion. Combining S-ketamine with a sub-effective dose of CP94253 (1 mg/kg) rescued S-ketamine's acute and sustained antidepressant-like effects, when CP94253 was administered 2 h prior to the FST. Co-administration of S-ketamine and CP94253 did not affect the plasma level of either compound, suggesting that the observed behavioral interaction could not be ascribed to a kinetic drug-drug interaction.

Conclusion:

5-HT1B receptor activation during testing appears to be critical for S-ketamine's antidepressant-like potentials in this model.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Dinamarca

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Dinamarca